Indications & Dose: MYELODYSPLASTIC SYNDROME IV/SC Adult 75mg/m2/day for 1 wk repeated q 4wks, dose may increase to 100mg/m2/day (if no benefits is observed after 2cycles/no toxicity other than nausea/vomiting)

Precautions: Renal impairment

ADR: Serious: Peripheral edema, chest pain, pallor, pitting edema, hypokalemia, thrombocytopenia, leukopenia, febrile neutropenia, myelosuppression, arthralgia, myalgia, URTI, pneumonia, hypertension, hypotension, tachycardia, cellulitis, hemorrhoids, hematoma, herpes simplex, lymphadenopathy, post procedural hemorrhage, Others: fever, fatigue, dizziness, depression, insomnia, pain, bruising, erythema, skin lesion, nausea, vomiting, constipation, weight loss, abdominal pain, injection site reaction, weakness, back pain, dyspnea, nasopharyngitis, epistaxis, crackles, gingival bleeding, stomatitis, weight loss, dysphagia, abdominal distension, rhinorrhea, wheezing, nasal congestion, sinusitis, night sweats, tongue ulceration, mouth hemorrhage

DDI: Others Pimecrolimus/Denosumab/Tacrolimus increases azacitidne levels, Vaccines (Live & inactivated)/BCG levels decreases, Vaccines (Live)/Leflunomide levels increases

Monitor: LFTs, electrolytes, CBC with differential & platelets, renal function test